Arbutus Biopharma

Arbutus Biopharma Provides Update on the Phase 2A Combination Trial with AB-729 and a Capsid Inhibitor

WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that while its partner, Assembly Biosciences, recently decided to discontinue development of its investigational hepatitis B virus core inhibitor candidate vebicorvir …

Arbutus Biopharma Provides Update on the Phase 2A Combination Trial with AB-729 and a Capsid Inhibitor Read More